Status:
RECRUITING
Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborating Sponsors:
URC-CIC Paris Descartes Necker Cochin
Conditions:
Lymphoproliferation Induced by HTLV-1
HTLV-1 Adult T-cell Lymphoma / Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- 18 years old or older
- HTLV-1 infected
- T lymphoproliferation induced by HTLV-1 (cohort 1)
- without T lymphoproliferation induced by HTLV-1 (cohort 2)
- informed and accepted the collection of data
- Exclusion Criteria
- \- Patients refusal of participation
Exclusion
Key Trial Info
Start Date :
March 23 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05237245
Start Date
March 23 2022
End Date
March 1 2027
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Necker Enfants Malades
Paris, France, 75015